Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that mid-sized, research-based pharmaceutical companies face a bleak long-term future: as their fates will be to merge with others, diversify into related fields such as generics, survive as niche players, or perish altogether. According to a controversial new report from Decision Resources, The Outlook for the World Pharmaceutical Industry to 2015, there seems to be little long-term future for companies outside the current top 15 to 20 pharma firms.

"It's really a numbers game," said Tracy DeGregorio, director at Decision Resources. "R&D expenditure for each of the top 12 companies approached or exceeded $2 billion, and for some it was well over $3 billion. An annual investment of this magnitude can be made only by a very limited number of firms, and is probably the lowest threshold for a company that wishes to stay in the game indefinitely. Mid-tier European pharmaceutical companies are at particular risk, as they are too numerous and too small."

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Large Metropolitan Markets Have Highest HMO Penetration Rates According to New Research from InterStudy Publications

View Now